We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Lifileucel

By: Madeline Johnston, MSN, RN, OCN®

Published In: Voice

Publication Date: 2024-06-25

Description

On February 16, 2024, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte cancer therapy for metastatic melanoma, lifileucel (Amtagvi™). Patients in the drug’s clinical trial experienced a significant decrease in tumor burden, and the median overall survival was 17.4 months.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Lifileucel

Description

ONS Drug Education

Related Topics